Biogen’s full Ph2 data for IgA nephropathy drug; Sanofi invests in obesity biotech

Plus, news about Novartis, CombiGene, ProQR and Aardvark Therapeutics:

Biogen presents full Phase 2 data for felzartamab: The drug, which was acquired in Biogen’s …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease

Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.

August 23, 2024

Biocytogen, Radiance partner for bispecific antibody-drug conjugate

Share this article The partnership aims to advance the development of a first-in-class fully human anti-HER2/TROP2 BsADC for cancer treatments. Credit: Spectral-Design/shutterstock.com. Biocytogen Pharmaceuticals and

January 9, 2024

3D screen printing technology enables fabrication of oral dosage forms with freely tailorable drug release profiles – technology and concept well suited for mass production – Biotech Investments

New York, 07/06/2023 / 08:42, EST/EDT – EQS Newswire – Laxxon Medical NEW YORK, NY / ACCESSWIRE / July 6, 2023 / A study published

July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.